Your dog was diagnosed with Multicentric B-Cell Lymphoma (Rescue/Relapse). Virtually all dogs with multicentric lymphoma will relapse after first-line therapy. Median first remission duration with CHOP is 6-11 months. Second remissions are typically shorter than first. Compare 8 treatment options for dogs including Rabacfosadine (Tanovea-CA1), CCNU (Lomustine) Rescue, MOPP Protocol — with survival times, costs, and what to expect during treatment.
Pet Cancer Options — Multicentric B-Cell Lymphoma (Rescue/Relapse)
Canine Oncology Treatment Guide
Multicentric B-Cell Lymphoma (Rescue/Relapse)
WHO Stage III-V
Round Cell
About This Cancer
When a dog with B-cell lymphoma initially responds to chemotherapy but the cancer later returns, this is termed a relapse. Treatment given at this point is called rescue therapy. Unfortunately, virtually all dogs treated for multicentric lymphoma will eventually relapse, typically after a first remission lasting six to eleven months. At relapse, the cancer cells may have developed some resistance to the drugs used initially, which is why second-line ('rescue') protocols use different agents. Second remissions can usually be achieved, but they tend to be shorter than the first, and each successive remission becomes progressively harder to obtain and briefer in duration. The choice of rescue protocol depends on which drugs were used first line, how long the first remission lasted, and the dog's overall condition. Despite the challenges, many dogs can still enjoy a good quality of life for several additional months with appropriate rescue therapy.
WHO Clinical Staging for Canine Lymphoma
Same staging system as first-line. Re-staging at relapse is important to assess disease extent.
Prognostic Factors(4)
Minimum Workup(5 steps)
Median Survival Time Comparison
How long the average patient survives with each treatment
Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.
Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.